These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker. Choi YJ; Seo JH; Shin KJ Bioorg Med Chem Lett; 2014 Feb; 24(3):880-3. PubMed ID: 24412109 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers. Woo HM; Lee YS; Roh EJ; Seo SH; Song CM; Chung HJ; Pae AN; Shin KJ Bioorg Med Chem Lett; 2011 Oct; 21(19):5910-5. PubMed ID: 21843937 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and calcium channel-modulating effects of alkyl (or cycloalkyl) 1,4-dihydro-2,6-dimethyl-3-nitro-4-pyridyl-5-pyridinecarboxylate racemates and enantiomers. Ramesh M; Matowe WC; Akula MR; Vo D; Dagnino L; Li-Kwong-Ken MC; Wolowyk MW; Knaus EE J Med Chem; 1998 Feb; 41(4):509-14. PubMed ID: 9484501 [TBL] [Abstract][Full Text] [Related]
33. Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. Melena J; Osborne NN Exp Eye Res; 2001 Apr; 72(4):393-401. PubMed ID: 11273667 [TBL] [Abstract][Full Text] [Related]
34. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Novelli A; Díaz-Trelles R; Groppetti A; Fernández-Sánchez MT Amino Acids; 2005 Mar; 28(2):183-91. PubMed ID: 15714253 [TBL] [Abstract][Full Text] [Related]
35. L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives. Budriesi R; Cosimelli B; Ioan P; Ugenti MP; Carosati E; Frosini M; Fusi F; Spisani R; Saponara S; Cruciani G; Novellino E; Spinelli D; Chiarini A J Med Chem; 2009 Apr; 52(8):2352-62. PubMed ID: 19323482 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers. Chikhale R; Thorat S; Pant A; Jadhav A; Thatipamula KC; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P Bioorg Med Chem; 2015 Oct; 23(20):6689-713. PubMed ID: 26385444 [TBL] [Abstract][Full Text] [Related]
37. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials. Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583 [TBL] [Abstract][Full Text] [Related]
38. Intracellular calcium elevation during plateau potentials mediated by extrasynaptic NMDA receptor activation in rat hippocampal CA1 pyramidal neurons is primarily due to calcium entry through voltage-gated calcium channels. Oda Y; Kodama S; Tsuchiya S; Inoue M; Miyakawa H Eur J Neurosci; 2014 May; 39(10):1613-23. PubMed ID: 24674276 [TBL] [Abstract][Full Text] [Related]
39. Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity. Yamamoto T; Niwa S; Iwayama S; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Yamamoto H; Shoji M Bioorg Med Chem; 2006 Aug; 14(15):5333-9. PubMed ID: 16616501 [TBL] [Abstract][Full Text] [Related]
40. New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Duque MD; Camps P; Torres E; Valverde E; Sureda FX; López-Querol M; Camins A; Prathalingam SR; Kelly JM; Vázquez S Bioorg Med Chem; 2010 Jan; 18(1):46-57. PubMed ID: 19954985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]